RIGL — Rigel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $479.56m
- $376.90m
- $294.28m
Annual cashflow statement for Rigel Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.9 | -58.6 | -25.1 | 17.5 | 367 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 12.9 | 12.9 | 8.59 | 11.6 | -28.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.72 | -29 | 9.52 | 0.153 | -19.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 5.88 | -73.8 | -5.74 | 31.5 | 75.7 |
| Capital Expenditures | -0.627 | -0.45 | -15 | -0.396 | 0 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -79.4 | 73.2 | 10.7 | 4.53 | -92.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -80 | 72.8 | -4.3 | 4.13 | -92.4 |
| Financing Cash Flow Items | 57.9 | -15.1 | -2.63 | -13.6 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 62.7 | 6.55 | 18.4 | -11.6 | 0.601 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -11.5 | 5.57 | 8.33 | 24 | -16.1 |